Dr. Colin F. Greineder is an Associate Professor of Emergency Medicine and Pharmacology and a member of the BioInterfaces Institute and the Max Harry Weil Institute for Critical Care Research at the University of Michigan in Ann Arbor, MI. He received his B.S. and M.D. at Yale University and completed his Emergency Medicine residency at the University of Michigan, receiving awards as a Medical Educator and Early Career Researcher.

After working for a short time as a community ER doctor, he returned to academia to pursue graduate and post-doctoral training in Pharmacology at the University of Pennsylvania, motivated largely by the lack of disease-modifying therapeutics for acute care illnesses. His research focuses on the design and testing of novel, affinity-targeted small molecule, protein, and nanoparticle therapeutics, with a particular focus on delivery of biotherapeutics to the brain, bone, lung, and joints.

Dr. Greineder’s work has been funded by five different NIH institutes, the Department of Defense, the Emergency Medicine Foundation, and the Society for Academic Emergency Medicine, where he now serves as Chair of the Grant Review Subcommittee. He is co-founder of Skeletalis, Inc., a Boston-based startup focused on commercialization of bone-targeted therapeutics for post-menopausal osteoporosis.

To learn more, visit the website of the Greineder Laboratory.